Skip to main content
    C

    Cerus Corporation (CERS)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $1.86
    -0.12 (-6.30%)

    Market Cap: $400.88M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Cerus Corporation (CERS) Earnings: Report Dates and Results

    Updated Nov 2, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Cerus (CERS) is expected to report earnings on Mar 1, 2027. In the quarter ended Sep 30, 2026, Cerus reported EPS of $0.00, above the -$0.01 estimate. It beat the EPS estimate in 4 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    43%(17/40)
    Avg Surprise
    +7.47%
    Streak
    1 Q

    Upcoming Estimates

    Reports Mar 1, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.01
    Range-$0.01 - $0.00
    6 analysts
    Revenue Consensus
    $67.55M
    Range$59.19M - $72.45M
    6 analysts
    Reports Apr 28, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.01
    Range-$0.01 - -$0.01
    1 analysts
    EPS RevisionsNo revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$0.00n/a
    60d ago$0.00n/a
    30d ago$0.00n/a
    7d ago$0.00n/a
    Current-$0.01
    Revenue Consensus
    $62.70M
    Range$58.29M - $66.40M
    3 analysts

    Next Report

    CERS has an expected report date of Mar 1, 2027.

    CERS Earnings Call

    The latest CERS earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, CERS beat 17, missed 12 and matched 11. Revenue for the quarter ended Sep 30, 2026 was $57.71M, up 9.5% from $52.70M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.00-$0.01-$0.02 - -$0.01+73.00%BeatN/A20 up, 0 downNov 2, 2026$57.71M
    Jun 30, 2026-$0.01-$0.01-$0.01 - -$0.010.00%In lineN/A20 up, 1 downJul 30, 2026$57.44M
    Mar 31, 2026-$0.01-$0.04-$0.04 - -$0.03+75.00%BeatN/A20 up, 1 downApr 30, 2026$53.66M
    Dec 31, 2025-$0.01-$0.01-$0.01 - $0.00-33.33%MissN/A20 up, 0 downMar 2, 2026$64.58M
    Sep 30, 2025$0.00-$0.02-$0.03 - -$0.02+99.50%BeatN/A20 up, 1 downNov 6, 2025$52.70M
    Jun 30, 2025-$0.03-$0.02-$0.03 - -$0.01-50.00%MissN/A21 up, 1 downAug 5, 2025$52.45M
    Mar 31, 2025-$0.04-$0.05-$0.07 - -$0.03+20.00%BeatN/A2N/AMay 1, 2025$43.24M
    Dec 31, 2024-$0.01-$0.01-$0.02 - -$0.010.00%In lineN/A40 up, 0 downFeb 20, 2025$56.75M
    Sep 30, 2024-$0.02-$0.03-$0.03 - -$0.03+33.33%BeatN/A60 up, 0 downOct 30, 2024$50.66M
    Jun 30, 2024-$0.03-$0.04-$0.06 - -$0.03+25.00%BeatN/A60 up, 0 downAug 1, 2024$50.52M
    Mar 31, 2024-$0.05-$0.04-$0.07 - -$0.04-25.00%MissN/A60 up, 0 downMay 2, 2024$43.40M
    Dec 31, 2023-$0.01-$0.02-$0.03 - -$0.01+50.00%BeatN/A50 up, 0 downMar 5, 2024$53.34M
    Sep 30, 2023-$0.03-$0.05-$0.06 - -$0.05+40.00%BeatN/A40 up, 0 downNov 2, 2023$47.25M
    Jun 30, 2023-$0.06-$0.06-$0.07 - -$0.040.00%In lineN/A50 up, 0 downAug 2, 2023$47.73M
    Mar 31, 2023-$0.09-$0.07-$0.09 - -$0.05-28.57%MissN/A40 up, 0 downMay 4, 2023$38.48M
    Dec 31, 2022-$0.08-$0.05-$0.06 - -$0.04-60.00%MissN/A40 up, 0 downFeb 28, 2023$51.32M
    Sep 30, 2022-$0.05-$0.05-$0.07 - -$0.040.00%In lineN/A51 up, 0 downNov 3, 2022$46.34M
    Jun 30, 2022-$0.06-$0.06-$0.08 - -$0.060.00%In lineN/A50 up, 0 downAug 4, 2022$47.63M
    Mar 31, 2022-$0.07-$0.08-$0.10 - -$0.06+12.50%BeatN/A50 up, 0 downMay 5, 2022$43.02M
    Dec 31, 2021-$0.05-$0.08-$0.08 - -$0.07+37.50%BeatN/A50 up, 0 downFeb 22, 2022$50.09M
    Sep 30, 2021-$0.07-$0.10-$0.10 - -$0.08+30.00%BeatN/A50 up, 0 downNov 2, 2021$42.10M
    Jun 30, 2021-$0.09-$0.09-$0.10 - -$0.090.00%In lineN/A4N/AAug 3, 2021$37.76M
    Mar 31, 2021-$0.10-$0.09-$0.11 - -$0.08-11.11%MissN/A5N/AMay 4, 2021$29.57M
    Dec 31, 2020-$0.09-$0.09-$0.10 - -$0.080.00%In lineN/A5N/AFeb 25, 2021$33.59M
    Sep 30, 2020-$0.08-$0.10-$0.12 - -$0.09+20.00%BeatN/A5N/AOct 29, 2020$29.19M
    Jun 30, 2020-$0.09-$0.10-$0.12 - -$0.10+10.00%BeatN/A4N/AAug 4, 2020$26.83M
    Mar 31, 2020-$0.10-$0.10-$0.13 - -$0.080.00%In lineN/A5N/AMay 5, 2020$24.64M
    Dec 31, 2019-$0.12-$0.12-$0.13 - -$0.110.00%In lineN/A4N/AFeb 20, 2020$26.49M
    Sep 30, 2019-$0.13-$0.12-$0.12 - -$0.10-8.33%MissN/A6N/AOct 30, 2019$22.85M
    Jun 30, 2019-$0.13-$0.12-$0.12 - -$0.09-8.33%MissN/A4N/AAug 1, 2019$22.48M
    Mar 31, 2019-$0.14-$0.11-$0.12 - -$0.09-27.27%MissN/A5N/AMay 7, 2019$21.96M
    Dec 31, 2018-$0.12-$0.11-$0.11 - -$0.10-9.09%MissN/A5N/AFeb 26, 2019$20.24M
    Sep 30, 2018-$0.11-$0.10-$0.11 - -$0.09-10.00%MissN/A5N/ANov 1, 2018$19.33M
    Jun 30, 2018-$0.10-$0.11-$0.13 - -$0.10+9.09%BeatN/A5N/AAug 2, 2018$19.47M
    Mar 31, 2018-$0.11-$0.11-$0.13 - -$0.100.00%In lineN/A5N/AMay 8, 2018$17.02M
    Dec 31, 2017-$0.10-$0.11-$0.15 - -$0.10+9.09%BeatN/A5N/AMar 8, 2018$22.57M
    Sep 30, 2017-$0.12-$0.16-$0.16 - -$0.14+25.00%BeatN/A3N/ANov 2, 2017$10.80M
    Jun 30, 2017-$0.16-$0.16-$0.17 - -$0.140.00%In lineN/A3N/AAug 3, 2017$9.53M
    Mar 31, 2017-$0.18-$0.16N/A-12.50%MissN/AN/AN/AMay 3, 2017$8.43M
    Dec 31, 2016-$0.13-$0.15N/A+13.33%BeatN/AN/AN/AMar 7, 2017$12.22M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.08, after -$0.11 the year before. It was -$0.62 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.08N/A
    Dec 31, 2024-$0.11N/A
    Dec 31, 2023-$0.19N/A
    Dec 31, 2022-$0.26N/A
    Dec 31, 2021-$0.31N/A
    Dec 31, 2020-$0.36N/A
    Dec 31, 2019-$0.52N/A
    Dec 31, 2018-$0.44N/A
    Dec 31, 2017-$0.56N/A
    Dec 31, 2016-$0.62N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,300 words across 8 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20266,3358
    2026Q2Jun 30, 20264,3105
    2026Q1Mar 31, 20265,6818
    2025Q4Dec 31, 20254,2417
    2025Q3Sep 30, 20254,4927
    2025Q2Jun 30, 20253,9117
    2025Q1Mar 31, 20255,82610
    2024Q4Dec 31, 20245,53910

    2026Q3 Earnings Call

    Opening remarks

    Timothy J. Lee Head of Investor Relations Thank you, and good afternoon. I would like to thank everyone for joining us today. As part of today's webcast, we are simultaneously displaying slides that you can follow. You can access the slides from the Investor Relations website at ir.cerus.com. With me on the call are Vivek K. Jayaraman, Cerus' president and chief executive officer; Kevin D. Green, Cerus' Chief Financial Officer; and Dr. Nina Mufti, Cerus' Senior Vice President, Research and Development. Cerus issued two press releases this afternoon: one announcing our financial results for the third quarter ended September 30, 2026, and describing the company's recent business highlights; the other announcing top-line results from our Phase III REDeS study. You can access copies of both announcements on the company's website at www.cerus.com. I would like to remind you that some of the statements we will make on this call relate to future events and performance rather than historical facts and are forward-looking statements. These include statements regarding financial outlook and performance, our business strategy and priorities, expected growth and market opportunities, clinical and regulatory activities, product launches and expansion, and other statements that are not historical fact. These forward-looking statements involve risks and uncertainties that can cause actual performance and results to differ materially. Please refer to the forward-looking statements slide accompanying today's webcast, today's press releases, and risk factors in our Form 10-Q for the quarter ended September 30, 2026, which we will file shortly, for important factors that can cause actual results to differ materially. We undertake no duty or obligation to update our forward-looking statements. On today's call, we will also be discussing non-GAAP financial measures, including non-GAAP adjusted EBITDA. These non-GAAP measures should be considered as a supplement to, and not a replacement for, measures presented in accordance with GAAP. For a reconciliation of non-GAAP financial measures to the most comparable GAAP financial measures, to the extent reasonably available, please refer to today's press release and the slide presentation available on our website. We will begin today with Vivek providing a business update and corporate highlights, followed by Kevin to review our financial results and expectations for the rest of 2026, and lastly, closing remarks from Vivek. And now it is my pleasure to introduce Vivek K. Jayaraman, Cerus' president and chief executive officer.

    Vivek K. Jayaraman President and Chief Executive Officer Thank you, Timothy, and good afternoon, everyone. We appreciate you joining us today. At Cerus, our mission is clear: to expand patient access to safer blood and establish INTERCEPT as the standard of care for transfused blood components globally. Our third-quarter kit sales represent nearly 800,000 doses of transfusable blood.

    Frequently Asked Questions About CERS

    When is Cerus's next earnings date?

    Cerus's next earnings report is expected for Mar 1, 2027.

    Did CERS beat earnings estimates last quarter?

    Yes. Cerus reported EPS of $0.00 for the quarter ended Sep 30, 2026, above the -$0.01 estimate, a 73.00% surprise.

    What EPS do analysts expect from CERS next quarter?

    The consensus EPS estimate for Cerus for the quarter ending Dec 31, 2026 is -$0.01 from 6 analysts, with estimates from -$0.01 to $0.00.

    How often does CERS beat earnings estimates?

    Cerus beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of +23.02%.